De­vel­op­ing a Sanofi cast-off, Im­pact Bio­med­i­cines now sub­ject of $7B Cel­gene ac­qui­si­tion deal

A start­up de­vel­op­ing the once-dis­card­ed fe­dra­tinib, a drug cast off from Sanofi due to safe­ty con­cerns back in 2013, is now the sub­ject of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.